HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Survival with cardiac-resynchronization therapy in mild heart failure.

AbstractBACKGROUND:
The Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy (MADIT-CRT) showed that early intervention with cardiac-resynchronization therapy with a defibrillator (CRT-D) in patients with an electrocardiographic pattern showing left bundle-branch block was associated with a significant reduction in heart-failure events over a median follow-up of 2.4 years, as compared with defibrillator therapy alone.
METHODS:
We evaluated the effect of CRT-D on long-term survival in the MADIT-CRT population. Post-trial follow-up over a median period of 5.6 years was assessed among all 1691 surviving patients (phase 1) and subsequently among 854 patients who were enrolled in post-trial registries (phase 2). All reported analyses were performed on an intention-to-treat basis.
RESULTS:
At 7 years of follow-up after initial enrollment, the cumulative rate of death from any cause among patients with left bundle-branch block was 18% among patients randomly assigned to CRT-D, as compared with 29% among those randomly assigned to defibrillator therapy alone (adjusted hazard ratio in the CRT-D group, 0.59; 95% confidence interval [CI], 0.43 to 0.80; P<0.001). The long-term survival benefit of CRT-D in patients with left bundle-branch block did not differ significantly according to sex, cause of cardiomyopathy, or QRS duration. In contrast, CRT-D was not associated with any clinical benefit and possibly with harm in patients without left bundle-branch block (adjusted hazard ratio for death from any cause, 1.57; 95% CI, 1.03 to 2.39; P=0.04; P<0.001 for interaction of treatment with QRS morphologic findings).
CONCLUSIONS:
Our findings indicate that in patients with mild heart-failure symptoms, left ventricular dysfunction, and left bundle-branch block, early intervention with CRT-D was associated with a significant long-term survival benefit. (Funded by Boston Scientific; ClinicalTrials.gov numbers, NCT00180271, NCT01294449, and NCT02060110.).
AuthorsIlan Goldenberg, Valentina Kutyifa, Helmut U Klein, David S Cannom, Mary W Brown, Ariela Dan, James P Daubert, N A Mark Estes 3rd, Elyse Foster, Henry Greenberg, Josef Kautzner, Robert Klempfner, Malte Kuniss, Bela Merkely, Marc A Pfeffer, Aurelio Quesada, Sami Viskin, Scott McNitt, Bronislava Polonsky, Ali Ghanem, Scott D Solomon, David Wilber, Wojciech Zareba, Arthur J Moss
JournalThe New England journal of medicine (N Engl J Med) Vol. 370 Issue 18 Pg. 1694-701 (May 01 2014) ISSN: 1533-4406 [Electronic] United States
PMID24678999 (Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Topics
  • Aged
  • Bundle-Branch Block (complications, therapy)
  • Cardiac Resynchronization Therapy
  • Combined Modality Therapy
  • Defibrillators, Implantable
  • Female
  • Follow-Up Studies
  • Heart Failure (complications, mortality, prevention & control, therapy)
  • Humans
  • Intention to Treat Analysis
  • Kaplan-Meier Estimate
  • Male
  • Middle Aged
  • Proportional Hazards Models
  • Severity of Illness Index
  • Stroke Volume
  • Ventricular Dysfunction, Left (complications)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: